Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $20.71 Average Price Target from Analysts

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have been assigned an average rating of “Moderate Buy” from the eight analysts that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $20.71.

A number of equities analysts have recently commented on the stock. TD Cowen upgraded shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 26th. HC Wainwright restated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, March 26th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Thursday, April 11th. Wedbush boosted their target price on Stoke Therapeutics from $13.00 to $17.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 26th. Finally, Canaccord Genuity Group lifted their price target on Stoke Therapeutics from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, March 26th.

Stoke Therapeutics Price Performance

NASDAQ:STOK opened at $12.02 on Wednesday. Stoke Therapeutics has a 1 year low of $3.35 and a 1 year high of $16.40. The stock’s fifty day moving average price is $9.93 and its two-hundred day moving average price is $6.47. The company has a market cap of $626.48 million, a P/E ratio of -5.07 and a beta of 0.82.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Monday, March 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.02. The company had revenue of $2.80 million for the quarter, compared to the consensus estimate of $3.70 million. On average, analysts expect that Stoke Therapeutics will post -2.28 earnings per share for the current fiscal year.

Insider Transactions at Stoke Therapeutics

In related news, major shareholder Skorpios Trust sold 3,600,000 shares of the firm’s stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $11.60, for a total transaction of $41,760,000.00. Following the transaction, the insider now directly owns 10,843,681 shares of the company’s stock, valued at approximately $125,786,699.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CFO Stephen J. Tulipano sold 4,116 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $25,107.60. Following the transaction, the chief financial officer now owns 20,746 shares in the company, valued at approximately $126,550.60. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Skorpios Trust sold 3,600,000 shares of the company’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $11.60, for a total transaction of $41,760,000.00. Following the sale, the insider now owns 10,843,681 shares of the company’s stock, valued at $125,786,699.60. The disclosure for this sale can be found here. In the last three months, insiders sold 3,622,741 shares of company stock worth $41,935,115. 12.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Dorsey & Whitney Trust CO LLC bought a new position in Stoke Therapeutics during the 3rd quarter worth approximately $43,000. Sherbrooke Park Advisers LLC purchased a new position in shares of Stoke Therapeutics in the third quarter worth $48,000. SG Americas Securities LLC bought a new stake in Stoke Therapeutics during the 3rd quarter valued at $53,000. BNP Paribas Financial Markets boosted its position in Stoke Therapeutics by 86.2% during the 1st quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock valued at $193,000 after buying an additional 6,636 shares during the period. Finally, Corton Capital Inc. purchased a new stake in Stoke Therapeutics during the 3rd quarter valued at $58,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.